Inhalable Dry Powder Formulations of siRNA and pH-Responsive Peptides with Antiviral Activity Against H1N1 Influenza Virus

Molecular Pharmaceutics

Volumn 12, Issue 3, 2015, Pages 910-921

  Liang, Wanling ^a   Chow, Michael Y T ^a   Lau, Pui Ngan ^b   Zhou, Qi Tony ^c   Kwok, Philip C L ^a   Leung, George P H ^a   Mason, A James ^d   Chan, Hak Kim ^c   Poon, Leo L M ^b   Lam, Jenny K W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SYDNEY   (Australia)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

influenza; pH responsive peptide; pulmonary delivery; RNA interference; small interfering RNA; spray drying

Indexed keywords

2,3 DIAMINOPROPIONIC ACID; HISTIDINE; MANNITOL; SMALL INTERFERING RNA; ANTIMICROBIAL CATIONIC PEPTIDE; ANTIVIRUS AGENT; LAH(4) PROTEIN, SYNTHETIC; PEPTIDE; POWDER;

A549 CELL LINE; AEROSOL; AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRY POWDER; DRY POWDER INHALER; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; MDCK CELL LINE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTION INDEX; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; VIRUS INHIBITION; VIRUS REPLICATION; AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHARMACEUTICS; POWDER;

ADMINISTRATION, INHALATION; AMINO ACID SEQUENCE; ANTIMICROBIAL CATIONIC PEPTIDES; ANTIVIRAL AGENTS; BASE SEQUENCE; BIOPHARMACEUTICS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; GENE SILENCING; HUMANS; HYDROGEN-ION CONCENTRATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR SEQUENCE DATA; PARTICLE SIZE; PEPTIDES; POWDERS; RNA, SMALL INTERFERING;

EID: 84924039536     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500745v     Document Type: Article

References (54)

1. Fraser, C.; Donnelly, C. A.; Cauchemez, S.; Hanage, W. P.; Van Kerkhove, M. D.; Hollingsworth, T. D.; Griffin, J.; Baggaley, R. F.; Jenkins, H. E.; Lyons, E. J. Pandemic potential of a strain of influenza A (H1N1): early findings Science 2009, 324, 1557-1561
2. Vijaykrishna, D.; Poon, L.; Zhu, H.; Ma, S.; Li, O.; Cheung, C.; Smith, G.; Peiris, J.; Guan, Y. Reassortment of pandemic H1N1/2009 influenza A virus in swine Science 2010, 328, 1529-1529
3. Hu, Y.; Lu, S.; Song, Z.; Wang, W.; Hao, P.; Li, J.; Zhang, X.; Yen, H.-L.; Shi, B.; Li, T. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance Lancet 2013, 381, 2273-2279
4. de Fougerolles, A.; Novobrantseva, T. siRNA and the lung: research tool or therapeutic drug? Curr. Opin. Pharmacol. 2008, 8, 280-285
5. Ge, Q.; Filip, L.; Bai, A.; Nguyen, T.; Eisen, H. N.; Chen, J. Inhibition of influenza virus production in virus-infected mice by RNA interference Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8676-81
6. Burnett, J. C.; Rossi, J. J.; Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnol. J. 2011, 6, 1130-1146
7. Lam, J. K.-W.; Liang, W.; Chan, H.-K. Pulmonary delivery of therapeutic siRNA Adv. Drug Delivery Rev. 2012, 64, 1-15
8. Barik, S. siRNA for influenza therapy Viruses 2010, 2, 1448-1457
9. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discovery 2009, 8, 129-138
10. Haasnoot, J.; Westerhout, E. M.; Berkhout, B. RNA interference against viruses: strike and counterstrike Nat. Biotechnol. 2007, 25, 1435-43
11. Watts, J. K.; Corey, D. R. Silencing disease genes in the laboratory and the clinic J. Pathol. 2012, 226, 365-79
12. Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA interference in the clinic: challenges and future directions Nat. Rev. Cancer 2011, 11, 59-67
13. Akhtar, S.; Benter, I. F. Nonviral delivery of synthetic siRNAs in vivo J. Clin. Invest. 2007, 117, 3623-3632
14. Abbate, V.; Liang, W.; Patel, J.; Lan, Y.; Capriotti, L.; Iacobucci, V.; Bui, T. T.; Chaudhuri, P.; Kudsiova, L.; Vermeer, L. S. Manipulating the pH response of 2,3-diaminopropionic acid rich peptides to mediate highly effective gene silencing with low-toxicity J. Controlled Release 2013, 172, 929-938
15. Lam, J. K.; Liang, W.; Lan, Y.; Chaudhuri, P.; Chow, M. Y.; Witt, K.; Kudsiova, L.; Mason, A. J. Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways J. Controlled Release 2012, 158, 293-303
16. Liang, W.; Kwok, P. C. L.; Chow, M. Y. T.; Tang, P.; Mason, A. J.; Chan, H.-K.; Lam, J. K. W. Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids Eur. J. Pharm. Biophar. 2014, 86, 64-73
17. Patton, J. S.; Platz, R. M. Pulmonary delivery of peptides and proteins for systemic action Adv. Drug Delivery Rev. 1992, 8, 179-196
18. Lomer, M. C. E.; Parkes, G. C.; Sanderson, J. D. Review article: Lactose intolerance in clinical practice-myths and realities Aliment. Pharmacol. Ther. 2008, 27, 93-103
19. Zhiqiang, W.; Yaowu, Y.; Fan, Y.; Jian, Y.; Yongfeng, H.; Lina, Z.; Jianwei, W.; Qi, J. Effective siRNAs inhibit the replication of novel influenza A (H1N1) virus Antiviral Res. 2010, 85, 559-561
20. Li, J.; Turnidge, J.; Milne, R.; Nation, R. L.; Coulthard, K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob. Agents Chemother. 2001, 45, 781-785
21. Pilcer, G.; Vanderbist, F.; Amighi, K. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties J. Pharm. Sci. 2009, 98, 1463-1475
22. Clark, A. R.; Hollingworth, A. M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers- implications for in vitro testing J. Aerosol Med. 1993, 6, 99-110
23. Zhou, Q.; Tong, Z.; Tang, P.; Citterio, M.; Yang, R.; Chan, H.-K. Effect of device design on the aerosolization of a carrier-based dry powder inhaler-a case study on Aerolizer® Foradile® AAPS J. 2013, 15, 511-522
24. de Boer, A. H.; Chan, H. K.; Price, R. A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? Adv. Drug Delivery Rev. 2012, 64, 257-274
25. Liang, W.; Mason, A. J.; Lam, J. K. Western blot evaluation of siRNA delivery by pH-responsive peptides Methods Mol. Biol. 2013, 986, 73-87
26. Takada, A.; Nail, S. L.; Yonese, M. Influence of ethanol on physical state of freeze-dried mannitol Pharm. Res. 2009, 26, 1112-1120
27. McSwiggen, J. A.; Seth, S. A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A Expert Opin. Biol. Ther. 2008, 8, 299-313
28. Betakova, T.; Svancarova, P. Role and application of RNA interference in replication of influenza viruses Acta Virol. 2013, 57, 97-104
29. Hayden, F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 2009, 48, S3-S13
30. Ge, Q.; McManus, M. T.; Nguyen, T.; Shen, C. H.; Sharp, P. A.; Eisen, H. N.; Chen, J. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 2718-2723
31. Ge, Q.; Eisen, H. N.; Chen, J. Use of siRNAs to prevent and treat influenza virus infection Virus Res. 2004, 102, 37-42
32. Tompkins, S. M.; Lo, C. Y.; Tumpey, T. M.; Epstein, S. L. Protection against lethal influenza virus challenge by RNA interference in vivo Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 8682-6
33. Genzel, Y.; Reichl, U. Continuous cell lines as a production system for influenza vaccines Expert Rev. Vaccines 2009, 8, 1681-1692
34. WHO information for molecular diagnosis of influenza virus in humans-update; World Health Organization: Geneva, Switzerland, 2011.
35. Schuck, S.; Manninen, A.; Honsho, M.; Füllekrug, J.; Simons, K. Generation of single and double knockdowns in polarized epithelial cells by retrovirus-mediated RNA interference Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4912-4917
36. Traini, D.; Young, P. M. Delivery of antibiotics to the respiratory tract: an update Expert Opin. Drug Delivery 2009, 6, 897-905
37. Vehring, R. Pharmaceutical particle engineering via spray drying Pharm. Res. 2008, 25, 999-1022
38. Littringer, E. M.; Mescher, A.; Eckhard, S.; Schröttner, H.; Langes, C.; Fries, M.; Griesser, U.; Walzel, P.; Urbanetz, N. A. Spray drying of mannitol as a drug carrier-the impact of process parameters on product properties Drying Technol. 2012, 30, 114-124
39. Pilcer, G.; Amighi, K. Formulation strategy and use of excipients in pulmonary drug delivery Int. J. Pharm. 2010, 392, 1-19
40. Bitko, V.; Musiyenko, A.; Shulyayeva, O.; Barik, S. Inhibition of respiratory viruses by nasally administered siRNA Nat. Med. 2005, 11, 50-55
41. Taratula, O.; Kuzmov, A.; Shah, M.; Garbuzenko, O. B.; Minko, T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA J. Controlled Release 2013, 171, 349-357
42. Healey, G. D.; Evans, N.; Hopkin, J. M.; Davies, G.; Walker, W. Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma J. Cell. Mol. Med. 2013, 17, 356-364
43. Huang, Z.-Y.; Kim, M.-K.; Kim-Han, T.-H.; Indik, Z. K.; Schreiber, A. D. Effect of locally administered Syk siRNA on allergen-induced arthritis and asthma Mol. Immunol. 2013, 53, 52-59
44. Fujita, Y.; Takeshita, F.; Kuwano, K.; Ochiya, T. RNAi therapeutic platforms for lung diseases Pharmaceuticals 2013, 6, 223-250
45. Jensen, D. K.; Jensen, L. B.; Koocheki, S.; Bengtson, L.; Cun, D.; Nielsen, H. M.; Foged, C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA J. Controlled Release 2012, 157, 141-148
46. Jensen, D. M. K.; Cun, D.; Maltesen, M. J.; Frokjaer, S.; Nielsen, H. M.; Foged, C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation J. Controlled Release 2010, 142, 138-145
47. Glover, W.; Chan, H.-K.; Eberl, S.; Daviskas, E.; Verschuer, J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers Int. J. Pharm. 2008, 349, 314-322
48. Daniher, D. I.; Zhu, J. Dry powder platform for pulmonary drug delivery Particuology 2008, 6, 225-238
49. Littringer, E. M.; Mescher, A.; Schroettner, H.; Achelis, L.; Walzel, P.; Urbanetz, N. Spray dried mannitol carrier particles with tailored surface properties-the influence of carrier surface roughness and shape Eur. J. Pharm. Biopharm. 2012, 82, 194-204
50. Littringer, E. M.; Noisternig, M. F.; Mescher, A.; Schroettner, H.; Walzel, P.; Griesser, U. J.; Urbanetz, N. A. The morphology and various densities of spray dried mannitol Powder Technol. 2013, 246, 193-200
51. Adi, H.; Young, P. M.; Chan, H.-K.; Agus, H.; Traini, D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease Eur. J. Pharm. Sci. 2010, 40, 239-247
52. Young, P. M.; Crapper, J.; Philips, G.; Sharma, K.; Chan, H.-K.; Traini, D. Overcoming dose limitations using the Orbital® multi-breath dry powder inhaler J. Aerosol Med. Pulm. Drug Delivery 2014, 27, 138-147
53. Sanders, N.; Rudolph, C.; Braeckmans, K.; De Smedt, S. C.; Demeester, J. Extracellular barriers in respiratory gene therapy Adv. Drug Delivery Rev. 2009, 61, 115-127
54. Rosenecker, J.; Naundorf, S.; Gersting, S.; Hauck, R.; Gessner, A.; Nicklaus, P.; Müller, R.; Rudolph, C. Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins J. Gene Med. 2003, 5, 49-60